

## Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation

*Acquisition to expand urology offerings for people living with overactive bladder*

MARLBOROUGH, Mass., Jan. 12, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB).

In the United States, nearly 30 million adults ages 40 and older have bothersome symptoms of OAB.<sup>1</sup> The condition can have a significant impact on quality of life, mental health, sleep, productivity and social activities.<sup>2</sup> One study found that the overall treatment rate for OAB, beyond behavioral and lifestyle adjustments, was approximately 19%.<sup>3</sup>

The eCoin system, approved by the U.S. Food and Drug Administration in 2022, is a coin-sized device that is placed under the skin, near the ankle, during a minimally invasive procedure. The device is intended for patients who have undergone a successful trial of percutaneous tibial nerve stimulation (PTNS) or for patients who are intolerant to or have an inadequate response to more conservative UUI treatments. Once implanted, the device intermittently and automatically stimulates the tibial nerve to help regulate how the brain communicates with the bladder. In the eCoin pivotal clinical trial, 68% of patients responded with at least a 50% reduction in UUI episodes.<sup>4</sup>

"The addition of the eCoin system to the Boston Scientific portfolio will enable us to expand into implantable tibial nerve stimulation (ITNS), a high-growth adjacency for our Urology business," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "ITNS technology complements our existing pelvic health product line, and we look forward to offering a more comprehensive set of treatment options to patients across the care continuum."

Boston Scientific expects to complete the acquisition in the first half of 2026, subject to customary closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2026 and is expected to be more dilutive on a GAAP basis due to acquisition-related net charges and amortization expense. Specific terms of the transaction have not been disclosed.

### About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at [www.bostonscientific.com](http://www.bostonscientific.com) and follow us on [LinkedIn](#).

### Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, the financial and business impact of the transaction and the anticipated benefits of the transaction, the closing of the transaction and the timing thereof, and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions, including our ability to achieve the anticipated benefits of the proposed transaction and successfully integrate Valencia Technologies' operations; business disruptions (including disruptions in relationships with employees, customers and suppliers) following the announcement and/or closing of the proposed transaction; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-

savings and growth initiatives; future business decisions made by us and our competitors; the conditions to the completion of the proposed transaction, including the receipt of any required regulatory approvals and clearances, may not be satisfied at all or in a timely manner; and the closing of the proposed transaction may not occur or may be delayed. These and any new risks and uncertainties, which may arise from time to time, are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.

CONTACTS:

Nate Gilbraith  
Media Relations  
+1 (701) 212-9589  
[nate.gilbraith@bsci.com](mailto:nate.gilbraith@bsci.com)

Lauren Tengler  
Investor Relations  
+1 (508) 683-4479  
[BSXInvestorRelations@bsci.com](mailto:BSXInvestorRelations@bsci.com)

---

<sup>1</sup> Coyne, et al. "National community prevalence of overactive bladder in the United States stratified by sex and age." Urology. Volume 77, Issue 5, P1081-1087, MAY 2011. DOI: <https://doi.org/10.1016/j.urology.2010.08.039>

<sup>2</sup> Reynolds, et al. "The Burden of Overactive Bladder on US Public Health." Curr Bladder Dysfunct Rep, Mar 2016.

<sup>3</sup> Mohamud H, et al. Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns. Neurourol Urodyn. 2025 Feb;44(2):319-329. doi: 10.1002/nau.25627.

<sup>4</sup> Rogers A, et al. Pivotal study of leadless tibial nerve stimulation with eCoin ® for urgency urinary incontinence: an open-label, single arm trial. Journal of Urology. August 2021. DOI: <https://doi.org/10.1097/JU.0000000000001733>

SOURCE Boston Scientific Corporation

---

<https://news.bostonscientific.com/2026-01-12-Boston-Scientific-Announces-Agreement-to-Acquire-Valencia-Technologies-Corporation>